Literature DB >> 27358339

Detecting depression in Parkinson disease: A systematic review and meta-analysis.

Zahra Goodarzi1, Kelly J Mrklas2, Derek J Roberts2, Nathalie Jette2, Tamara Pringsheim2, Jayna Holroyd-Leduc2.   

Abstract

BACKGROUND: Failure to detect depression in patients with Parkinson disease (PD) can lead to worsened outcomes for patients and caregivers. Accurate identification of depression would enable practitioners to provide comprehensive care for their patients with PD.
METHODS: Our objective was to examine the diagnostic accuracy of tools for detecting depression in adult outpatients with PD. We searched MEDLINE, PsycINFO, and EMBASE (inception to December 1, 2015), gray literature, and bibliographies of included studies. The pooled prevalence of depression across studies and diagnostic accuracy estimates were calculated using random-effects models. Diagnostic accuracy estimates were calculated across the best-reported cutoffs from each study and across specific cutoffs, when feasible.
RESULTS: Out of 8,184 citations, 21 studies were included, evaluating 24 tools, with 4 amenable to meta-analysis. The pooled prevalence of major depression was 22.9% (95% confidence interval [CI] 18.1-27.7). The 15-item Geriatric Depression Scale (GDS-15) had a pooled sensitivity of 0.81 (95% CI 0.64-0.91) and specificity of 0.91 (95% CI 0.87-0.94). The most sensitive cutoff for the GDS-15 was 5 at 0.91 (95% CI 0.83-1.00). The Beck Depression Inventory I/Ia had a pooled sensitivity of 0.79 (95% CI 0.61-0.90) and specificity of 0.85 (95% CI 0.79-0.90). The Montgomery-Åsberg Depression Rating Scale yielded a pooled sensitivity of 0.77 (95% CI 0.69-0.83) and specificity of 0.92 (95% CI 0.79-0.97). The Unified Parkinson's Disease Rating Scale had a pooled sensitivity of 0.72 (95% CI 0.64-0.79) and specificity of 0.80 (95% CI 0.70-0.87). All estimates had heterogeneity.
CONCLUSIONS: There are several valid tools for detecting depression in patients with PD. Practitioners should choose one that fits their clinical practice.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Year:  2016        PMID: 27358339      PMCID: PMC4977107          DOI: 10.1212/WNL.0000000000002898

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  54 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

2.  Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease.

Authors:  Marcos Hortes Nisihara Chagas; Vitor Tumas; Sonia Regina Loureiro; Jaime E C Hallak; Clarissa Trzesniak; João Paulo Machado de Sousa; Guilherme Gustavo Ricciopo Rodrigues; Alaor Santos Filho; José Alexandre S Crippa
Journal:  Parkinsonism Relat Disord       Date:  2009-08-05       Impact factor: 4.891

3.  Meta-analysis in the design and monitoring of clinical trials.

Authors:  R DerSimonian
Journal:  Stat Med       Date:  1996-06-30       Impact factor: 2.373

4.  Recognizing depression in patients with Parkinson's disease: accuracy and specificity of two depression rating scale.

Authors:  Cláudia Débora Silberman; Jerson Laks; Cláudia Figueiredo Capitão; Cláudia Soares Rodrigues; Irene Moreira; Eliasz Engelhardt
Journal:  Arq Neuropsiquiatr       Date:  2006-06       Impact factor: 1.420

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Diagnostic accuracy and agreement across three depression assessment measures for Parkinson's disease.

Authors:  Alexander W Thompson; Honghu Liu; Ron D Hays; Wayne J Katon; Rebecca Rausch; Natalie Diaz; Erin L Jacob; Stefanie D Vassar; Barbara G Vickrey
Journal:  Parkinsonism Relat Disord       Date:  2010-11-17       Impact factor: 4.891

Review 7.  Depression rating scales in Parkinson's disease: A critical review updating recent literature.

Authors:  Elizabeth Torbey; Nancy A Pachana; Nadeeka N W Dissanayaka
Journal:  J Affect Disord       Date:  2015-06-10       Impact factor: 4.839

8.  The Inventory for Depressive Symptomatology (IDS): preliminary findings.

Authors:  A J Rush; D E Giles; M A Schlesser; C L Fulton; J Weissenburger; C Burns
Journal:  Psychiatry Res       Date:  1986-05       Impact factor: 3.222

Review 9.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

10.  Screening for depression in Parkinson's disease: the performance of two screening questions.

Authors:  Sarah Baillon; Michael Dennis; Nelson Lo; James Lindesay
Journal:  Age Ageing       Date:  2013-10-16       Impact factor: 10.668

View more
  44 in total

Review 1.  A practical approach to detection and treatment of depression in Parkinson disease and dementia.

Authors:  Zahra Goodarzi; Zahinoor Ismail
Journal:  Neurol Clin Pract       Date:  2017-04

Review 2.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

3.  Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson's Disease, and Multiple Sclerosis: Diagnosis and Treatment.

Authors:  Susan K Conroy; Katherine B Brownlowe; Thomas W McAllister
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

4.  Considerations before initiating therapy in Parkinsonism: basing on the quality of life.

Authors:  Shu-Jin He; Zhen-Yang Liu; Yu-Jie Yang; Cong Shen; Yu-Jie Du; Xin-Yue Zhou; Jue Zhao; Yi-Min Sun; Ke Yang; Jian-Jun Wu; Feng-Tao Liu; Jian Wang
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

5.  Self-perception and determinants of color vision in Parkinson's disease.

Authors:  Alexander U Brandt; Hanna G Zimmermann; Timm Oberwahrenbrock; Justine Isensee; Thomas Müller; Friedemann Paul
Journal:  J Neural Transm (Vienna)       Date:  2017-11-15       Impact factor: 3.575

6.  APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.

Authors:  Thomas F Tropea; Sharon X Xie; Jacqueline Rick; Lana M Chahine; Nabila Dahodwala; Jimit Doshi; Christos Davatzikos; Leslie M Shaw; Vivianna Van Deerlin; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2017-11-23       Impact factor: 10.338

Review 7.  Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders.

Authors:  Luigi Trojano; Costanza Papagno
Journal:  Neurol Sci       Date:  2017-10-16       Impact factor: 3.307

8.  Depression Screening from Voice Samples of Patients Affected by Parkinson's Disease.

Authors:  Yasin Ozkanca; Miraç Göksu Öztürk; Merve Nur Ekmekci; David C Atkins; Cenk Demiroglu; Reza Hosseini Ghomi
Journal:  Digit Biomark       Date:  2019-06-12

9.  MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.

Authors:  Atsuhiro Fujita; Yuko Fujita; Yaoyu Pu; Lijia Chang; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2019-08-15       Impact factor: 4.530

Review 10.  Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers).

Authors:  Pio Conti; Alessandro Caraffa; Gianpaolo Ronconi; Chiara M Conti; Spiros K Kritas; Filiberto Mastrangelo; Lucia Tettamanti; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.